1 / 6

Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY

This study evaluates the efficacy of Ledipasvir-Sofosbuvir, with or without GS-9669 or GS-9451, in treatment-naïve patients with HCV Genotype 1 and unfavorable baseline treatment characteristics. The results show high SVR rates at 12, 24, and 48 weeks of treatment.

kristywalker
Download Presentation

Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentNaïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIH SYNERGY KohliA, et al. 21st CROI. 2014:Abstract 27LB.

  2. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIH SYNERGY Trial: Features Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  3. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIH SYNERGY Trial: Features 0 6 12 18 24 Week Treatment NaïveAll stages fibrosis LDV-SOF n =20 SVR12 Treatment NaïveCirrhosis excluded LDV-SOF+ GS-9669 n = 20 SVR12 Treatment NaïveCirrhosis excluded LDV-SOF + GS-9451 n = 20 SVR12 Abbreviations: LDV-SOF= ledipasvir-sofosbuvir Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyGS-9669: 500 mg once dailyGS-9451: 80 mg once daily Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  4. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIH SYNERGY Trial: Participants Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  5. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIH SYNERGY Trial: Features NIH SYNERGY: SVR 12 by Treatment Regimen 20/20 19/20 20/20 Source: Kohli A, et al. 21st CROI. 2014:Abstract 27LB.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related